A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 12,546
- 试验地点
- 7
- 主要终点
- Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)
研究概览
简要总结
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk. The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and CV death, in a population with no history of known CVD who are at moderate risk of major CHD events (approximately 10-20% 10 year CHD risk). This corresponds to a patient population mean 10-year CVD risk of approximately 30%. Subjects are treated in a standard care setting and may receive treatment for the underlying risk factors as defined by the treating physician. Outcome events will be adjudicated by an Endpoint Adjudication Committee and the study will be monitored by an independent Data Safety Monitoring Board.
详细描述
Summary of substantial Protocol amendments
Amendment #2 from 09-APR-2008:
- Systolic blood pressure (SBP) limit of 170 mmHg has been added to the exclusion criteria
- Exclusion of patients currently taking anticoagulant medication
- A longer interval between the daily dose of study drug and ibuprofen
- Revised wording in moderate risk definitions for coronary heart disease (CHD) and cerebrovascular disease (CVD): "To evaluate the clinical effects of a 100 mg/day enteric-coated acetylsalicylic acid versus placebo in the reduction of CVD events in patients at moderate risk of major CHD events (approximately 10 to 20% 10-year CHD risk; approximately 20 to 30% 10-year risk of CVD). This corresponds to a patient population mean 10-year CVD risk of approximately 30%."
Amendment #3 from 02-JAN-2009
• Increase in the number of allowed risk factors for males, age is no longer a risk factor
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males aged 55 years and above with 2 to 4 risk factors. Male Risk Factors:
- •Elevated cholesterol (Tchol>200 mg/dL or LDL>130 mg/dL; as measured at screening) irrespective of current treatment
- •Current smoking: defined as any cigarette smoking in the past 12 months
- •Low HDL cholesterol (HDL<40 mg/dL; as measured at screening)
- •Elevated blood pressure (SBP>140 mmHg; as measured at screening)
- •Currently on any medication to treat high blood pressure
- •Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years)
- •Females aged 60 and above with 3 or more risk factors. Female Risk Factors:
- •Elevated cholesterol (Tchol>240 mg/dL or LDL>160 mg/dL; as measured at screening) irrespective of current treatment
- •Current smoking: defined as any cigarette smoking in the past 12 months
- •Low HDL cholesterol (HDL<40 mg/dL; as measured at screening)
- •Elevated blood pressure (SBP>140 mmHg; as measured at screening)
- •Currently on any medication to treat high blood pressure
- •Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years)
- •An understanding and willingness to comply with trial procedures and has given written informed consent to participate in the trial
排除标准
- •History of a documented vascular event, such as MI, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant arrhythmias, or congestive heart failure or vascular intervention
- •Patients who are at higher than moderate risk on the basis of their diabetes status, other factors known to the investigator, or the currently used national risk score
- •Known contraindications to the study drug, e.g. hypersensitivity to acetylsalicylic acid
- •Recent (in the past year) history of gastrointestinal or genitourinary bleeding or other bleeding disorders
- •Active diagnosed and documented reflux esophagitis
- •Patients presenting with any medical condition, or psychiatric or substance abuse disorder, that, in the opinion of the investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study
- •Lactating women or women of childbearing potential
- •Severe liver disease or damage based on the clinical judgment of the investigator
- •Severe renal disease or damage based on the clinical judgement of the investigator
- •A definite indication for acetylsalicylic acid therapy, other antiplatelet drug, or anticoagulant in the opinion of the physician
- •A history of asthma induced by administration of salicylates or substances with a similar action, notably NSAIDS
- •Chronic, frequent (> 5 days/month) use of NSAIDs (including aspirin, or aspirin containing products), COX-2 inhibitors or metamizole
- •Current participation in any other trials involving investigational products within 30 days prior to the Screening Visit
- •Current use of an anticoagulant medication
- •Sitting systolic blood pressure greater than 170 mmHg
研究组 & 干预措施
Acetylsalicylic acid (Aspirin, BAYE4465)
Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
干预措施: Aspirin (Acetylsalicylic acid, BAYE4465) (Drug)
Placebo
Participants received 1 tablets of matching placebo orally once daily.
干预措施: Placebo (Drug)
结局指标
主要结局
Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic Attack)
时间窗: Until follow-up (approximate 6 years)
The primary efficacy endpoint was a composite outcome consisting of the first occurrence of confirmed MI, stroke, cardiovascular death, UA, TIA. The time to event was defined as the number of days from the date of randomization to the date of the event confirmed by adjudication. The numbers of days for milestones when 1%, 2%, 3% and 4% of the subjects have reached endpoint events were estimated from Kaplan-Meier-Analyses.
次要结局
- Time to the First Occurrence of the Composite Outcome of Cardiovascular Death, MI, or Stroke (Ischemic, Hemorrhagic, or Unknown)(Until follow-up (approximate 6 years))
- Time to the First Occurrence of the Individual Components of the Primary: Non-fatal MI, Total MI, Non-fatal Stroke, Total Stroke, Cardiovascular Death, UA and TIA(Until follow-up (approximately 6 years))
- Time to All-cause Mortality, the First Occurrence of All Cancers Excluding Non-melanoma Skin Cancer (NMSC) and the First Occurrence of Colon Cancer(Until follow-up (approximately 6 years))
- Incidence of All-cause Mortality, All Cancers Excluding Non-melanoma Skin Cancer and Colon Cancer(Until follow-up (approximately 6 years))
- Incidence of Confirmed MI, Stroke, Cardiovascular Death, UA, and TIA Separately(Until follow-up (approximately 6 years))